

### Remarks

Claims 1 to 8 were pending. By this Amendment, claims 1 to 8 have been amended. No new matter is presented by the amendments and entry is respectfully requested. Accordingly, claims 1 to 8, as amended, are now pending and before the Examiner.

The Examiner rejected claims 1 to 8 under 35 U.S.C. § 112, first paragraph, as allegedly not enabling.

In response, applicants traverse the Examiner's rejections. The terms "solvate" and "prodrugs" are defined and fully enabled by the specification, *inter alia*, on page 132 and 134 and well within the ability of one of skill in the art to make and use the claimed invention based on the disclosure. The enablement of "solvate" and "prodrugs" does not require more than this and this has been recognized repeatedly by the PTO, which has allowed similar claims containing the term "solvate" for related glucocorticoid mimetic applications by at least five different examiners, *see, e.g.*, U.S. Patent Nos. 6,858,627; 6,903,215; 6,960,581; 7,074,806; 7,186,864; and 7,189,758. Nonetheless, because this subject matter is not of current interest to applicants and in order to expedite prosecution, applicants have amended the claims to remove solvates and prodrugs. Accordingly, applicants respectfully request that the Examiner reconsider and withdraw these rejections.

Applicants respectfully submit that all the pending claims are allowable and therefore solicit a Notice of Allowance for all of the pending claims. If the Examiner feels that a telephone interview would be helpful in advancing prosecution of this application, the Examiner is invited to contact the attorney below.

Respectfully submitted,

/timothy witkowski/

---

Timothy X. Witkowski, Reg. No. 40,232  
Attorney for Applicants

BOEHRINGER INGELHEIM CORPORATION  
Patent Department  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT 06877  
Telephone: (203) 798-4310  
Facsimile: (203) 798-4408